Results offers the skills of an experienced and entrepreneurial healthcare team dedicated to the life sciences sector having closed more than 75 successful transactions to date. Our clients trust us because of our strong international relationships with shareholders and management teams across the healthcare lifecycle. We combine expert financial capabilities with backgrounds in science, healthcare and IT that will bring value to your business.

We work with businesses and entrepreneurs to help articulate the ideal equity story, target the right investors and negotiate the best deal.

• Full service offering for Healthcare M&A transactions, for both buyers and sellers
• Advice on strategic options for healthcare businesses and assets
• Expert guidance on development capital, utilisation of investments or finance for MBO/MBI
• Support for licensing transactions for research assets and marketed products

Healthcare Sub-Sectors

Our highly specialised, global team works together seamlessly across six focus areas in the healthcare sector.

Healthcare Deals

Jul 2022
has divested its API site in Rhode Island, USA, to
Jun 2022
A Kester Capital-backed company
has received investment from
Jun 2022
has been acquired by
A company backed by GTCR and The Carlyle Group
May 2022
A subsidiary of Servier
has divested its anti-LAG-3 monoclonal antibody to
A subsidiary of Sino Biopharmaceutical Limited
Mar 2022
has divested its Ringaskiddy, Ireland, manufacturing facility
Mar 2022
has divested its Boucherville, Canada manufacturing facility
Feb 2022
has received investment from
Jan 2022
has divested its API manufacturing site in Cramlington, UK, to
Nov 2021
has received investment from
Nov 2021
has invested in
company name confidential

Latest Insights

27th September 2022

Pharma Commercialisation Services Update – September 2022

Welcome to our latest update on the outsourced Pharma Commercialisation Services sector.  As well as our usual update on M&A activity, this report takes a deep dive into one of the biggest challenges businesses are currently facing – the War for Talent. A phrase first coined by McKinsey in the late ’90s but one that […]

8th September 2022

Pharma Licensing: the why, the how and a few things to get right!

Platform or asset licensing has increasingly been utilised across the bio-pharmaceutical industry to achieve Corporate objectives by sharing intellectual property (IP).  IP includes patents and know-how and third-party proprietary technologies, compounds and products, and can be used to build on existing therapeutic areas, expand into different geographies or to diversify portfolios.  A pharma licensing deal […]

Corporate News
3rd August 2022

We are joining forces with Canaccord Genuity

We are very excited to share that we have agreed to join forces with Canaccord Genuity – a leading full-service investment bank serving growth companies in the middle market.  This is an important milestone in our journey and we wanted to update you on why we’ve taken this decision and what it means for you. […]